The potential role of MLC phosphatase and MAPK signalling in the pathogenesis of vascular dysfunction in heart failure.
The clinical syndrome of heart failure is associated with both a resting vasoconstriction and reduced sensitivity to nitric oxide mediated vasodilatation, and this review will focus on the role of myosin light chain (MLC) phosphatase in the pathogenesis of the vascular abnormalities of heart failure. Nitric oxide mediates vasodilatation by an activation of guanylate cyclase and an increase in the production of cGMP, which leads to the activation of the type I cGMP-dependent protein kinase (PKGI). PKGI then activates a number of targets that produce smooth muscle relaxation including MLC phosphatase. MLC phosphatase is a holoenzyme consisting of three subunits; a 20 kD subunit of unknown function, an approximately 38-kD catalytic subunit and a myosin targeting subunit (MYPT1). Alternative splicing of a 31 bp 3 exon generates MYPT1 isoforms, which differ by a COOH-terminus leucine zipper (LZ). Further, PKGI-mediated activation of MLC phosphatase requires the expression of a LZ+ MYPT1. Congestive heart failure is associated with a decrease in LZ+ MYPT1 expression, which results in a decrease in the sensitivity to cGMP-mediated smooth muscle relaxation. Beyond their ability to reduce afterload, angiotensin converting enzyme (ACE) inhibitors have a number of beneficial effects that include maintaining the expression of the LZ+ MYPT1 isoform, thereby conserving normal sensitivity to cGMP-mediated vasodilatation, as well as differentially regulating genes associated with mitogen activated protein kinase (MAPK) signalling. ACE inhibition reduces circulating angiotensin II and thus limits the downstream activation of MAPK signalling pathways, possibly preventing the alteration of the vascular phenotype to preserve normal vascular function.
Ogut
Ozgur
O
Division of Cardiovascular Diseases, Mayo Medical School, Rochester, MN 55905, USA.
Brozovich
Frank V
FV
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D020013:Calcium Signaling; D002216:Captopril / Q000494:pharmacology; D006152:Cyclic GMP / Q000378:metabolism; D015870:Gene Expression / Q000187:drug effects; D006333:Heart Failure / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology*; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D009131:Muscle, Smooth, Vascular / Q000503:physiopathology; D043263:Myosin-Light-Chain Phosphatase / Q000235:genetics / Q000378:metabolism*; D014661:Vasoconstriction / Q000502:physiology*
D000806:Angiotensin-Converting Enzyme Inhibitors; D002216:Captopril; D043263:Myosin-Light-Chain Phosphatase; D006152:Cyclic GMP